VITALITY: Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology - Baseline Data

Simms, V and Ferrand, R. 2024. VITALITY: Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology - Baseline Data. [Online]. London School of Hygiene & Tropical Medicine, London, United Kingdom. Available from: https://doi.org/10.17037/DATA.00003868.

Simms, V and Ferrand, R. VITALITY: Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology - Baseline Data [Internet]. London School of Hygiene & Tropical Medicine; 2024. Available from: https://doi.org/10.17037/DATA.00003868.

Simms, V and Ferrand, R (2024). VITALITY: Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology - Baseline Data. [Data Collection]. London School of Hygiene & Tropical Medicine, London, United Kingdom. https://doi.org/10.17037/DATA.00003868.

Description

The VITamin D for AdoLescents with HIV to reduce musculoskeletal morbidity and ImmunopaThologY (VITALITY) trial is a phase III two-site, individually randomised, double-blinded, placebo-controlled trial. Participants were randomised 1:1 to receive weekly vitamin D and daily 500mg calcium carbonate supplementation or placebo for 48 weeks. Participants were followed for a further 48 weeks to investigate the sustainability of intervention effect. 842 children aged 11-19 years with perinatally-acquired HIV resident in greater Harare (Zimbabwe site) or within Lusaka (Zambia site) were recruited. The baseline dataset contains information on the participants' living environment, health status, received treatments, exercise levels, and other information.

Methods

Description of data capture

Participants completed a researcher-administered questionnaire on demographic and social characteristics and medical history, and a dietary assessment. They gave a blood sample for CD4 and HIV viral load tests (full blood count in Zambia). They had anthropometric measurements (height, sitting height and weight in both countries; waits, hip, calf, triceps circumfererence, skinfold thickness, Tanita bioimedance assessment Bodpod in Zambia). They had a total body and lumbar spine DXA scan. Those in Zimbabwe had a pQCT scan and a hand X-ray using the iDXA. A blood sample was taken for measurements of vitamin D pathway metabolites, bone turnover markers and iPTH, and for additional immunology studies in Zambia. 123 participants in each country had a rectal swab.

Data capture method

Interview: Face-to-face, Lab observation, Physical measurements and tests

Data Collection Period

From	To
4 February 2021	23 November 2021

Date (Date submitted to LSHTM repository)

11 June 2024

Language(s) of written materials

English, Shona

People & Groups

Data Creators	Simms, V and Ferrand, R
Associated roles	Bandason, T (Data Manager) and Filteau, S (Researcher)
LSHTM Faculty/Department	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology & International Health (2023-) Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Research Group	The Health Research Unit Zimbabwe (THRUZIM)
Participating Institutions	London School of Hygiene & Tropical Medicine, London, United Kingdom, Biomedical Research and Training Institute, Zimbabwe, University Teaching Hospital Lusaka, Lusaka, Zambia

Projects

Funders

Project	Funder	Grant Number	Funder URI
VITamin D for AdoLescents with HIV to reduce musculoskeletal morbidity and ImmunopaThologY (VITALITY): an individually randomised, double-blinded placebo-controlled triaL	European and Developing Countries Clinical Trials Partnership	RIA2018CO-2512	http://dx.doi.org/10.13039/501100001713